Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs

References

• Palella FL Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001;183(10):1466–1475.
   Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.
   PubMed Web of Science ®Google Scholar
• Negredo E, Moltó J, Muñoz-Moreno JA, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther. 2004;9(3):335–342.
   Web of Science ®Google Scholar
• Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naïve chronically HIV-1-infected individuals. AIDS. 2003;17(8):1151–1156.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Abadi J, Rosenberg M, et al. Pharmacokinetics (PK) of tenofovir DF (TDF) oral suspension in HIV-1 infected children between 2 and 8 years of age. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, CA, USA.
   Google Scholar
• Ramos JT, Gonzalez Tome MI, Rojo P, Fernandez Ibieta M, Vargas K, Garcia-Pinal L. Experience with tenofovir disoproxil fumarate (TDF) in heavily pretreated HIV-infected children Paper presented at the 15th International AIDS Conference; July 11–16, 2004; Bangkok, Thailand.
   Google Scholar
• Hazra R, Gani RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):e846–e854.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated January 12, 2012. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed December 25, 2012.
   Google Scholar
• World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Revised. Geneva: WHO; 2010. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed October 15, 2012.
   Google Scholar
• Panel on Antiretroviral Therapy and Medical Management of HIVInfected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated August 11, 2011. Available from http://aidsinfo.nih.gov/Contentfiles/PediatricGuidelines.pdf. Accessed October 15, 2012.
   Google Scholar
• Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105.
   PubMed Web of Science ®Google Scholar
• Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo, antiretrovirus activities of (R)-9- (2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother. 1993;37(2):332–338.
   PubMed Web of Science ®Google Scholar
• Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother. 1998;42(3):612–617.
   PubMed Web of Science ®Google Scholar
• Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res. 1997;36(2):91–97.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Interim guidance: pre-exposure prophylxais for the prevention of HIV in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–68.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated US public health service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2005;54(RR-9):1–17.
   Google Scholar
• Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prohylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep. 2005;54(RR-2):1–20.
   PubMedGoogle Scholar
• Siberry G, Williams P, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26(9):1151–1159.
   PubMed Web of Science ®Google Scholar
• van der Straten A, Van Damme L, Haberer J, Bangsberg D. Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26(7):F13–F19.
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
   PubMed Web of Science ®Google Scholar
• Thigpen M, Debabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Paper presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 17–20, 2011; Rome, Italy.
   Google Scholar
• Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP Study. Paper presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 17–20, 2011; Rome, Italy.
   Google Scholar
• Family Health International. FHI statement on the FEM-PrEP HIV prevention study: FHI to initiate orderly closure of FEM-PrEP. 2011. Available from: http://www.mtnstopshiv.org/sites/default/files/attachments/FEM-PrEP%20Statement%20FINAL1.pdf. Accessed September 1, 2012.
   Google Scholar
• Family Health International. VOICE HIV prevention trial continues, but researchers suspend oral tenofovir arm because of futility. Available from: http://www.fhi360.org/en/AboutFHI/Media/Releases/res_VOICE.htm. Accessed September 1, 2012.
   Google Scholar
• Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother. 2003;37(6):849–859.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37(7):944–950.zzzz
   PubMed Web of Science ®Google Scholar
• Viread [package insert]. 2012. Gilead Sciences, Foster City, CA, USA. Available from: http://www.gilead.com/pdf/viread_pi.pdf. Accessed September 5, 2012.
   Google Scholar
• Barrios A, García-Benayas T, González-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18(6):960–963.
   Web of Science ®Google Scholar
• James CW, Steinhaus MC, Szabo S, et al. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24(3):415–418.
   Web of Science ®Google Scholar
• Murphy MD, O’Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis. 2003;36(8):1082–1085.
   Web of Science ®Google Scholar
• Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37(3):c41–c43.
   Web of Science ®Google Scholar
• Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 2007;17(2):90–92, 99–104, C3.
   Google Scholar
• Scott JD, Wolfe PR, Bolan RK, Guyer W. Serious renal impairment occurs rarely with use of tenofovir DF. HIV Clin Trials. 2006;7(2): 55–58.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):e108–e116.
   PubMed Web of Science ®Google Scholar
• Woodward CLN, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10(8):482–487.
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164–172.
   PubMed Web of Science ®Google Scholar
• Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711–e718.
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir. Antimicrob Agents Chemother. 2002;46:716–723.
   PubMed Web of Science ®Google Scholar
• McArthur JC, Sacktor N, Selnes OA. Human immunodeficiency virus-associated dementia. Semin Neurol. 1999;19(2):129–150.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789–1799.
   PubMed Web of Science ®Google Scholar
• Dennis BC, Houff SA, Han DY, Schmitt FA. Development of neurocognitive disorders in HIV/AIDS. Neurobehav HIV Med. 2011;2011(3):9–18.
   Google Scholar
• Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009;82(2):A99–A109.
   Web of Science ®Google Scholar
• Sacktor N, Nakasujja, Skolasky R, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009;49(5):780–786.
   Web of Science ®Google Scholar
• Letendre S, Ellis R, Ances B, McCutchan J. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55.
   PubMedGoogle Scholar
• Cespedes M, Aberg J. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29(10):865–874.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175(4):963–966.
   Web of Science ®Google Scholar
• McArthur JC, McClemon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol. 1997;42(5):689–698.
   Web of Science ®Google Scholar
• Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol. 1997;42:679–688.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002;59(6):923–928.
   PubMedGoogle Scholar
• Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol. 2008;82(15):7591–7600.
   Web of Science ®Google Scholar
• Heaton RK, Clifford DB, Franklin DR Jr. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096.
   PubMed Web of Science ®Google Scholar
• Smith R, Chernoff M, Rutstein R, et al. The long-term impact of HIV disease severity on cognitive and adaptive functioning during childhood and adolescence. Paper presented at the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada.
   Google Scholar
• Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
   PubMed Web of Science ®Google Scholar
• Ellis R, Heaton R, Letendre S, et al. Higher CD4 nadir is associated with reduced rates of HIV-associated neurocognitive disorders in the CHARTER study: potential implications for early treatment initiation. Paper presented at the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada.
   Google Scholar
• Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45(2):174–182.
   PubMed Web of Science ®Google Scholar
• Dawes S, Suarez P, Casey CY, et al. Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol. 2008;30(6):613–626.
   PubMed Web of Science ®Google Scholar
• Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53(1):557–593.
   PubMedGoogle Scholar
• Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis. 2008;197(Suppl 3):S294–S306.
   Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357–365.
   PubMed Web of Science ®Google Scholar
• Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359–1366.
   PubMed Web of Science ®Google Scholar
• Robertson K, Jiang H, Kumwenda J, et al. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study A5199, the International Neurological Study. Clin Infect Dis. 2012;55(6):868–876.
   Web of Science ®Google Scholar
• Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27(4):336–343.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol. 2004;61(11):1699–1704.
   PubMedGoogle Scholar
• O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4): 407–414.
   PubMed Web of Science ®Google Scholar
• Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naïve patients: a systematic review. AIDS Rev. 2010;12(2):67–75.
   PubMed Web of Science ®Google Scholar
• Cavalcante GIT, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci. 2010;120(12): 739–745.
   PubMed Web of Science ®Google Scholar
• Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999;180(3):862–864.
   PubMed Web of Science ®Google Scholar
• Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care. 2009;8(5):318–322.
   Google Scholar
• Adkins JC, Noble S. Efavirenz. Drugs. 1998;56(6):1055–1064.
   PubMed Web of Science ®Google Scholar
• Bickel M, Stephan C, Rottmann C, et al. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J Infect Dis. 2005;37:520–522.
   PubMed Web of Science ®Google Scholar
• Gutiérrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41(11):1648–1653.
   PubMed Web of Science ®Google Scholar
• Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS. 2002;16(9):1201–1215.
   PubMed Web of Science ®Google Scholar
• Blanch J, Corbella B, García F, Parellada E, Gatell JM. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001;33(2): 270–271.
   PubMed Web of Science ®Google Scholar
• Lochet P, Peyriere H, Lotthé A, Mauboussins JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4(1):62–66.
   PubMedGoogle Scholar
• Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1): 71–75.
   PubMed Web of Science ®Google Scholar
• Hasse B, Günthard F, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005;40(3):e22–e23.
   Web of Science ®Google Scholar
• Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33–42.
   PubMed Web of Science ®Google Scholar
• Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 2006;3(1):1.
   Google Scholar
• Best B, Letendre S, Koopmans P, et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012;59(4):376–381.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–260.
   PubMed Web of Science ®Google Scholar
• Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther. 2006;11(2): 263–265.
   Web of Science ®Google Scholar
• Rotger M, Colombo S, Furrer H, Décosterd L, Buclin T, Telenti A. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther. 2007;12(1):115–118.
   Web of Science ®Google Scholar
• HIV-druginteractions.org. Tenofovir efavirenz interaction report. Available from: http://www.hiv-druginteractions.org/interactions.aspx. Accessed September 1, 2012.
   Google Scholar